Capital Flow Monitor · Sponsors · CIK 2126389
Human Biotech, Inc.
77 NEW STREET, CAMBRIDGE, MA, 02138 · 617-898-8824
Biotechnology · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$10.0M
Sold
$10.0M
% sold
100.0%
Investors
6
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | D ·current | 506(b) | $10.0M | $10.0M | 100.0% | 6 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Agustin Javier Lopez-Marquez — Executive Officer / Director / Promoter, Cambridge, MA
-
Errik B. Anderson — Director, Cambridge, MA
2 other raises
- Alloy Therapeutics, Inc. $30.0M of $40.0M · 75.1%
- Cantai Therapeutics, Inc. $3.0M of $3.0M · 100.0%
- Andrew Danielsen — Director, Cambridge, MA
-
Dusan Perovic — Director, Cambridge, MA
8 other raises
- Deviation Co-Invest LLC - Deviate IV $447K of $447K · 100.0%
- Deviation Co-Invest LLC - Deviate V $913K of $913K · 100.0%
- Deviation Co-Invest LLC - Deviate III $828K of $828K · 100.0%
- Deviation Co-Invest LLC - Deviate II $10.3M of $10.3M · 100.0%
- Deviation Co-Invest LLC - Deviate I $6.2M of $6.2M · 100.0%
- Deviation Capital V LP $0 of —
- Freeform Future Corp. $58.9M of $67.1M · 87.8%
- Gameto, Inc. $44.0M of $44.0M · 100.0%
- Ankit Saxena — Executive Officer, Cambridge, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.